Program
IBI302
Also written as “IBI302 8mg dose”, “Low dose IBI302” and “High dose IBI302”.
Its studies are mostly in Macular Degeneration · Macular Edema, led by Innovent Biologics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Innovent Biologics | 83 open or running | phase 3since Jul 25, 2023 | Jan 15, 2019 | Dec 31, 2026phase 2 · NCT06908876 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 15, 2019First study: phase 1 study in Neovascular Age-related Macular DegenerationFirst studyNCT03814291 · 31 enrolled · China
- Apr 24, 2020Phase 1 study in Neovascular Age-related Macular DegenerationNCT04370379 · 18 enrolled · China
- Mar 25, 2021Phase 2 study in Neovascular Age-related Macular DegenerationNCT04820452 · 231 enrolled · China
- Nov 15, 2021Phase 2 study in Neovascular Age-related Macular DegenerationNCT05961007 · 234 enrolled · China
- May 20, 2022Phase 2 study in Neovascular Age-related Macular DegenerationNCT05403749 · 132 enrolled · China
- Jul 25, 2023Phase 3 study in Neovascular Age-related Macular DegenerationNCT05972473 · 600 enrolled · China
- Mar 27, 2025Phase 2 study in Diabetic Macular OedemaNCT06908876 · 150 enrolled · China
- Nov 24, 2025Phase 2 study in Neovascular Age-related Macular DegenerationNCT07275840 · 800 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 2 study in Diabetic Macular OedemaNCT06908876
- Feb 28, 2027Primary completion: phase 3 study in Neovascular Age-related Macular DegenerationNCT05972473
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07275840Neovascular Age-related Macular Degeneration · China | 2 | Recruiting | Aug 30, 2026 | 800 |
| NCT06908876Diabetic Macular Oedema · China | 2 | Active, not recruiting | Dec 31, 2026 | 150 |
| NCT05972473Neovascular Age-related Macular Degeneration · China | 3 | Active, not recruiting | Feb 28, 2027 | 600 |
| NCT05403749Neovascular Age-related Macular Degeneration · China | 2 | Completed | May 13, 2024 | 132 |
| NCT05961007Neovascular Age-related Macular Degeneration · China | 2 | Suspended | Oct 31, 2023 | 234 |
| NCT04820452Neovascular Age-related Macular Degeneration · China | 2 | Completed | Jan 13, 2023 | 231 |
| NCT04370379Neovascular Age-related Macular Degeneration · China | 1 | Completed | Apr 30, 2021 | 18 |
| NCT03814291Neovascular Age-related Macular Degeneration · China | 1 | Completed | Mar 5, 2020 | 31 |
How it is read
Names in the registry
- “IBI302”, 9 entries
- “IBI302 8mg dose”, 1 entry
- “Low dose IBI302”, 1 entry
- “High dose IBI302”, 1 entry
- “dose 1 IBI302”, 1 entry
Codes read as this program: IBI302.
Conditions, from the studies’ own filings
- Macular Degeneration, 6 studies
- Macular Edema, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.